First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity
Authors (first, second and last of 5)
Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms.
CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), and Sociedad Española de Inmunologia-Grupo Española de InmunoTerapia (SEI-GEIT).
CIMT: http://www.cimt.eu/home
CCIC: http://www.immunotherapycancer.ca/
JACI: http://www.jaci.jp/eng/index.html
NIBIT: http://www.nibit.org/index.php
SEI-GEIT: http://www.inmunologia.org/grupos/home.php?UpOm5=M&Upfqym5uom=GK
CITIM: http://www.canceritim.org 94% of authors who answered a survey reported that they would definitely publish or probably publish in the journal againJournal information
- Editor-in-Chief
-
- Haidong Dong
- Publishing model
- Hybrid (Transformative Journal). Learn about publishing Open Access with us
Journal metrics
- 5.442 (2019)
- Impact factor
- 4.781 (2019)
- Five year impact factor
- 34 days
- Submission to first decision
- 154 days
- Submission to acceptance
- 570,099 (2020)
- Downloads
Latest issue
Latest articles
-
-
Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program
Authors (first, second and last of 9)
-
RB1CC1 functions as a tumor-suppressing gene in renal cell carcinoma via suppression of PYK2 activity and disruption of TAZ-mediated PDL1 transcription activation
Authors (first, second and last of 8)
-
Tumour draining lymph node-generated CD8 T cells play a role in controlling lung metastases after a primary tumour is removed but not when adjuvant immunotherapy is used
Authors (first, second and last of 13)
-
Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies
Authors (first, second and last of 5)
Journal updates
-
COVID-19 and impact on peer review
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
-
Announcing new Editor-in-Chief: Dr. Haidong Dong
The journal is pleased to announce Dr. Haidong Dong has been named the new Editor-in-Chief of Cancer Immunology, Immunotherapy, effective January 1, 2020.
Societies, partners and affiliations
About this journal
- Electronic ISSN
- 1432-0851
- Print ISSN
- 0340-7004
- Abstracted and indexed in
-
- AGRICOLA
- BIOSIS
- Biological Abstracts
- CNKI
- Chemical Abstracts Service (CAS)
- Current Contents/ Life Sciences
- Dimensions
- EBSCO Academic Search
- EBSCO Biomedical Reference Collection
- EBSCO Discovery Service
- EBSCO STM Source
- EMBASE
- Elsevier Biobase
- Google Scholar
- Institute of Scientific and Technical Information of China
- Japanese Science and Technology Agency (JST)
- Journal Citation Reports/Science Edition
- Medline
- Naver
- OCLC WorldCat Discovery Service
- Pathway Studio
- ProQuest Biological Science Database
- ProQuest Central
- ProQuest Health & Medical Collection
- ProQuest Health Research Premium Collection
- ProQuest Immunology Abstracts
- ProQuest Medical Database
- ProQuest Natural Science Collection
- ProQuest Pharma Collection
- ProQuest Public Health Database
- ProQuest SciTech Premium Collection
- ProQuest-ExLibris Primo
- ProQuest-ExLibris Summon
- Reaxys
- SCImago
- SCOPUS
- Science Citation Index
- Science Citation Index Expanded (SciSearch)
- Semantic Scholar
- TD Net Discovery Service
- UGC-CARE List (India)
- Copyright information
